Clinical trials: Hypertension,Essential
Hypertension
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
- Trial name
- NCT00171405
- Testing
- aliskiren
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Novartis
Stage 1 Hypertension, Stage 2 Hypertension
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
- Trial name
- NCT01508026
- Testing
- Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3
- Where
- 413 sites in United States
- Volunteers
- 4,161 people
- Sponsor
- Forest Laboratories
Essential Hypertension
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects.
- Trial name
- NCT02345044
- Testing
- CS-3150, eplerenone
- Where
- Japan
- Volunteers
- 426 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT06465264
- Testing
- Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2
- Where
- China
- Volunteers
- 499 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
- Trial name
- EASE (NCT00546754)
- Testing
- losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Essential Hypertension
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
This is a multi-center, randomized, placebo-controlled, time-lagged, parallel-group study in healthy and hypertensive subjects to evaluate safety and tolerability of the vaccine CYT006-AngQb.
- Trial name
- NCT00500786
- Testing
- CYT006-AngQb
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Cytos Biotechnology AG
Essential Hypertension
FimasaRtan-basEd BP Targets After Drug SwitcHing
The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in…
- Trial name
- FRESH (NCT03649646)
- Where
- South Korea
- Volunteers
- 4,542 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.
- Trial name
- NCT00343551
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 654 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Moxonidine in Indian Patients
The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.
- Trial name
- NCT00160277
- Testing
- Moxonidine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Solvay Pharmaceuticals
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
- Trial name
- NCT05476354
- Testing
- Irbesartan/Amlodipine low, Irbesartan/Amlodipine high, Irbesartan
- Where
- South Korea
- Volunteers
- 271 people
- Sponsor
- Handok Inc.
Hypertension,Essential
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.
- Trial name
- NCT05462535
- Testing
- Amosartan Plus Tab.
- Where
- South Korea
- Volunteers
- 4,785 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
- Trial name
- NCT00591578
- Testing
- Azilsartan Medoxomil, Valsartan
- Where
- 88 sites in United States, Chile and 2 more
- Volunteers
- 984 people
- Sponsor
- Takeda
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
- Trial name
- NCT05931224
- Where
- South Korea
- Volunteers
- 346 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension,Essential, Systolic Hypertension
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately.
- Trial name
- NCT05086523
- Testing
- Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 28 people
- Sponsor
- BackBeat Medical Inc
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421375
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and telmisartan 40 mg plus HCTZ 12.5 mg in patients with…
- Trial name
- NCT00326768
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg, Telmisartan 80 mg/HCTZ 12.5 mg
- Where
- 3 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx